Concert Pharmaceuticals, Inc. (CNCE) financial statements (2022 and earlier)

Company profile

Business Address 65 HAYDEN AVENUE
LEXINGTON, MA 02421
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:141,600130,000106,400153,300203,20096,200142,200
Cash and cash equivalents141,63677,20253,04317,77027,66540,55592,510
Short-term investments1,46354,73558,770143,069175,50055,63049,680
Other undisclosed cash, cash equivalents, and short-term investments(1,499)(1,937)(5,413)(7,539)351510
Receivables2183,1773325711552770
Contract with customer, asset   16,000
Deferred costs15 143    
Other undisclosed current assets8,4969,5479,98010,2782,3791,5021,838
Total current assets:150,329142,724116,855180,149205,73497,729144,108
Noncurrent Assets
Operating lease, right-of-use asset8,5858,9689,252
Property, plant and equipment5,2426,3637,7538,9192,1652,1992,346
Restricted cash and investments1,1571,1571,1571,1571,557400400
Other noncurrent assets35196 346778
Other undisclosed noncurrent assets  2,3582,3222,246  
Total noncurrent assets:14,98716,53920,61612,3986,0022,6662,824
TOTAL ASSETS:165,316159,263137,471192,547211,736100,395146,932
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,3174,6294,9655,8604,3783,3664,126
Accounts payable2,6062308811,277658545501
Accrued liabilities1,0947098621,1268778111,047
Employee-related liabilities3,6173,6903,2223,0672,7972,0102,503
Taxes payable   39046 75
Deferred revenue  7,783
Debt  268    
Deferred revenue and credits1,5461,2741,330
Contract with customer, liability1,413
Other undisclosed current liabilities8,8035,5494,2521,4765219301,171
Total current liabilities:16,12010,17817,2688,7496,4455,5706,627
Noncurrent Liabilities
Long-term debt and lease obligation13,91015,06515,996    
Operating lease, liability13,91015,06515,996
Liabilities, other than long-term debt7,6232,8582,75011,9708,8599,2319,670
Deferred revenue and credits8,8599,2319,670
Accounts payable and accrued liabilities28108     
Deferred revenue7,5952,7502,750
Contract with customer, liability9,120
Deferred rent credit   2,850
Other undisclosed noncurrent liabilities15,438  4,088   
Total noncurrent liabilities:36,97117,92318,74616,0588,8599,2319,670
Total liabilities:53,09128,10136,01424,80715,30414,80116,297
Stockholders' equity
Stockholders' equity attributable to parent112,225131,162101,457167,740196,43285,594130,635
Common stock34312423232222
Additional paid in capital461,765400,636296,145284,369273,059257,461251,793
Accumulated other comprehensive loss(76)(58)(31)(137)(407)(7)(18)
Accumulated deficit(349,498)(269,447)(194,681)(116,515)(76,243)(171,882)(121,162)
Total stockholders' equity:112,225131,162101,457167,740196,43285,594130,635
TOTAL LIABILITIES AND EQUITY:165,316159,263137,471192,547211,736100,395146,932

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues32,5787,9021,07710,505143,89117466,729
Revenue, net143,89117456,729
Gross profit:32,5787,9021,07710,505143,89117466,729
Operating expenses(110,086)(80,549)(80,092)(66,089)(51,242)(51,341)(41,941)
Operating income (loss):(77,508)(72,647)(79,015)(55,584)92,649(51,167)24,788
Nonoperating income (expense)461,2022,9992,7994,122447(185)
Investment income, nonoperating461,2022,9872,7871,336447124
Other nonoperating income (expense)  12122,786 (309)
Interest and debt expense    (1,432) (29)
Income (loss) from continuing operations before equity method investments, income taxes:(77,462)(71,445)(76,016)(52,785)95,339(50,720)24,574
Other undisclosed income from continuing operations before income taxes      29
Income (loss) from continuing operations before income taxes:(77,462)(71,445)(76,016)(52,785)95,339(50,720)24,603
Income tax expense (benefit) 85 (313)300 (429)
Net income (loss):(77,462)(71,360)(76,016)(53,098)95,639(50,720)24,174
Other undisclosed net loss attributable to parent(2,589)(3,406)(2,150)(2,926)   
Net income (loss) attributable to parent:(80,051)(74,766)(78,166)(56,024)95,639(50,720)24,174
Undistributed earnings (loss) allocated to participating securities, basic    (444)
Net income (loss) available to common stockholders, basic:(80,051)(74,766)(78,166)(56,024)95,195(50,720)24,174
Other undisclosed net income available to common stockholders, diluted    15  
Net income (loss) available to common stockholders, diluted:(80,051)(74,766)(78,166)(56,024)95,210(50,720)24,174

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(77,462)(71,360)(76,016)(53,098)95,639(50,720)24,174
Other comprehensive income (loss)    95,239(50,709)24,170
Comprehensive income (loss):(77,462)(71,360)(76,016)(53,098)190,878(101,429)48,344
Other undisclosed comprehensive loss, net of tax, attributable to parent(2,607)(3,433)(2,044)(2,656)   
Comprehensive income (loss), net of tax, attributable to parent:(80,069)(74,793)(78,060)(55,754)190,878(101,429)48,344

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: